BTG2
BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
Overview
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 6 cohorts (4 activating, 2 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
- 1 · What it is
BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.
- 2 · What goes wrong in cancer
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner.
- 3 · How drugs use it
No product in this corpus aims at BTG2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:1131 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P78543 (protein name, function text, keywords and locations (REST API)); CIViC gene BTG2 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen BTG2 (driver in 6 cohorts (Act 4, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors. Modulates transcription regulation mediated by ESR1. Locus 1q32.1 (HGNC).
- Non-Hodgkin lymphoma: IntOGen driver in 2 cohorts (MLYM, NHL)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 3 cohorts (DLBCLNOS)
- Chronic lymphocytic leukaemia: IntOGen driver in 1 cohort (CLLSLL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BTG2" OR ABSTRACT:"BTG2" OR TITLE:"BTG anti-proliferation factor 2" OR ABSTRACT:"BTG anti-proliferation factor 2" OR TITLE:"PC3" OR ABSTRACT:"PC3" OR TITLE:"TIS21" OR ABSTRACT:"TIS21" OR TITLE:"MGC126063" OR ABSTRACT:"MGC126063" OR TITLE:"MGC126064" OR ABSTRACT:"MGC126064") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BTG2, not a curated reading list.